Alpha-synuclein structure, functions, and interactions

Area of Science:

• Neuroscience
• Biomarker Discovery
• Neurodegenerative Diseases

Background:

• Clinical diagnosis of Parkinson's disease (PD) often occurs after substantial nerve cell damage in the substantia nigra.
• Early detection of PD is critical for implementing treatments to slow disease progression and prevent toxic aggregate accumulation.

Approach:

• This review focuses on alpha-synuclein (α-syn) as a potential molecular biomarker for early PD detection.
• Detailed examination of α-syn's role in Lewy body formation and its aggregated, fibrillar structure.

Key Points:

• Alpha-synuclein (α-syn) is a key component of Lewy bodies, characteristic of Parkinson's disease.
• Aggregated and fibrillar forms of α-syn are implicated in PD pathogenesis.
• Identifying α-syn in its early stages could enable timely therapeutic interventions.

Conclusions:

• Alpha-synuclein (α-syn) presents significant potential as a biomarker for the early diagnosis of Parkinson's disease.
• Further research into α-syn biomarkers may lead to strategies to halt or slow PD progression.
• Early detection via α-syn could revolutionize Parkinson's disease treatment approaches.